MIRACL


Also found in: Acronyms, Wikipedia.
Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering Cardiology. A trial that asked whether early, rapid and profound cholesterol-lowering therapy with atorvastatin reduces early recurrent ischaemic events in patients with unstable angina or non-Q-wave MI
Conclusion A primary endpoint of major acute coronary events (MACE) occurred in 14.8% of atorvastatin patients and 17.4% of placebo patients (p = 0.05). Atorvastatin reduced the risk of ischaemia (6.2% vs. 8.4%; p = 0.02), but did not reduce the risk of MACE. Stroke occurred in 12 atorvastatin patients and 24 placebo patients (p = 0.04)

MIRACL

Cardiology A clinical trial–Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering
Mentioned in ?
References in periodicals archive ?
In addition to the present MIRACL concept, Miller cites the possibility of a laser using oxygen and iodine to achieve about half the wavelength of the hydrogen fluoride combination, or 1.
That's why MIRACL, and the solutions and services built using it, are in use in hundreds of organizations across the world, including BAE Systems, Hitachi, Intel, Panasonic, Toyota and many others.
the MIRACL and HPS studies) have shown significant stroke reduction even in the absence of dyslipidemia.
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
The MIRACL Study demonstrated that atorvastatin treatment during the acute phase of ACS reduced recurrent ischemic events (8).
MIRACL is the first trial to demonstrate that the clinical benefit of aggressive lipid-lowering therapy can be achieved within the critical months (16 weeks) following an acute coronary event.
MIRACL is a four-month study of Lipitor in patients with acute coronary syndromes.
MIRACL is a four-month study of patients with unstable angina measuring the time to an ischemic event.
More recently, TRW built and demonstrated the world's only megawatt-class lasers including the MIRACL (Mid-Infrared Advanced Chemical Laser).